Navigation Links
Amazing Treatment Relieves Serious Back Pain Without Dangerous Drugs, Injections or Surgery!
Date:12/14/2007

CHICAGO, Dec. 14 /PRNewswire/ -- Non-surgical, spinal decompression is probably the last back pain treatment you will ever need. And you can forget about popping toxic pills, struggling through exercise programs...and...unnecessary and risky injections and surgery...because with this amazing technology - for most people - they are a thing of the past.

Dr. Thea Flock is Chicagoland's most respected authority on relieving severe back and leg pain. Dr. Flock says, "I enable people to live longer using non-invasive techniques without the use of drugs, injections or surgery."

Dr. Flock has treated many Chicagoland residents offering them a solution to their severe low back and leg pain. Patients from Florida to California and as far away as Lima, Peru have sought out her treatment programs and have found relief.

Dr. Flock is a powerful, and educational interview. She will tell your audience:

-- Why most medications often fail

-- 8 causes of low back pain

-- The worst and best things you can do for low back pain at home

-- 6 warning signs of severe back and leg pain that everyone must know

-- How you can have diminished pain and increased function in less than

5 weeks

-- How can Dr. Flock guarantee diminished pain (No other doctor I know of

is willing to make a guarantee)

Dr. Flock has been featured in many local newspapers and publications including the M.D. News. Flock lectures to many different groups educating people on severe low back pain and the treatments available. Dr. Flock offers a free report entitled "The Severe Back, Sciatica, and Disc Pain Guide" and her website, http://www.flockspinal.com is a great educational resource to learn more about severe back pain.

Flock states, "I am thrilled to be able to provide relief to my patients who haven't responded to other treatments. Often times these are patients who have given up hope of ever being pain free. I believe this treatment will become as common in the treatment of back pain as laser eye surgery has become as a treatment for nearsightedness."

Dr. Thea Flock makes for a great interview and can be reached at 630-771-9662.

For further information contact: Dr. Thea Flock, 630-771-9662

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Flock Spinal Center, S.C.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
7. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
8. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
9. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
10. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
11. Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):